S-P China move
This article was originally published in The Tan Sheet
Schering-Plough establishes Shanghai Schering-Plough Pharmaceutical Co., Ltd., as a wholly owned operation in Shanghai, expanding its presence in the Chinese market, the firm says Aug. 12. The new operation is the result of S-P's acquisition of its former joint venture partners' shares and is part of S-P's "long-term global geographic expansion strategy," Chairman and CEO Fred Hassan says in a release. The company entered into an agreement in 1994 with two local joint-venture partners in China, Shanghai Pharmaceutical Industry Co., Ltd., and Shanghai Pharmaceutical Group Co., Ltd., to manufacture, market and distribute allergy and skin-care products in the country. Hassan says establishing the Shanghai operation "represents another step in our journey to transform Schering-Plough into a global high-performance health care company"...
You may also be interested in...
Dr Reddy’s Laboratories has become the third Revlimid ANDA sponsor to settle patent litigation action with Bristol Myers Squibb’s Celgene. However, the Indian company will join Alvogen in not being able to launch before first settler Natco, which has partnered with Teva’s Watson.
Strides is expanding its presence in synthetic injectables via a new company, SteriScience, while keeping its biologics injectables business under Stelis. A head start with existing IP assets and those from a new joint venture with Brooks Labs will enable the fledgling firm to file its first ANDA in fiscal 2021, with break-even foreseen in two years.
The US FDA has been skeptical about remote testing, but independent consultant (and former Abbott human factors director) Ed Israelski predicts the pandemic may bring a change.